BioSpace News Archive

Business

Merck & IRBM announce pioneering collaboration to advance peptide therapeutics

IRBM signs collaboration agreement with Merck & Co., Inc, Kenilworth, NJ, USA to advance peptide therapeutics

September 12, 2018
·
2 min read
Policy

Recro Pharma Provides Regulatory Update for IV Meloxicam

Company Anticipates NDA Resubmission by the End of September 2018

September 12, 2018
·
6 min read
DEP® irinotecan outperforms in pancreatic cancer model

DEP® irinotecan outperforms in pancreatic cancer model

September 12, 2018
·
7 min read
NHS England announces groundbreaking new personalised therapy for children with cancer

NHS patients to benefit from Europe’s first full access deal on breakthrough CAR-T therapy.

September 12, 2018
·
3 min read
Business

CURE Pharmaceutical Expands Distribution of CUREfilm Technology with First Licensing Agreement

CURE grants cannabis leader rights to its proprietary drug delivery technology in markets around the world

September 12, 2018
·
3 min read
Job Trends

SureClinical Announces SureCTMS, First Mobile eClinical Trial Management System

SureCTMS™ delivers the first clinical trial management system with an easy-to-use, mobile-first design for web, Apple and Android devices. Includes integrated document management, Adobe Digital Certificate signing, automated workflows, dashboard analytics, and SureNetwork access.

September 12, 2018
·
4 min read
Pharm Country

JADAK Broadens Machine Vision Capabilities for Improved Speed and Mechanical Precision

Adds Smart Cameras to Complement Existing Solutions

September 12, 2018
·
2 min read
Business

Nostrum CEO Defends Martin Shkreli as Company Increases Antibiotic Price by 400 Percent

Nirmal Mulye, chief executive officer of Missouri-based Nostrum Laboratories, is looking to take over Martin Shkreli’s mantle of being the poster-boy for drastic drug price increases.

September 12, 2018
·
2 min read
·
Alex Keown
Policy

In Negotiations of 1,000 Opioid Lawsuits, Purdue Pharma Offers Free Opioid Therapy

Purdue Pharma, best known for being the manufacturer of opioid drug OxyContin, is offering free doses of a treatment for opioid abuse as part of negotiations in more than 1,000 lawsuits.

September 12, 2018
·
3 min read
·
Mark Terry
Drug Development

Gilead News: Arthritis Drug, Precision BioSci Deal and Chief Medical Officer Change

Gilead Sciences had a lot of news lately. First off, Gilead and Belgium-based Galapagos NV announced results from their FINCH 2 Phase III clinical trial of filgotinib in adults with moderately-to-severely active rheumatoid arthritis.

September 12, 2018
·
3 min read
·
Mark Terry